Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) has raised several points of debate. We quantified the proportion of individuals meeting the JUPITER criteria, determined their risk profile, and their risk of coronary heart disease (CHD) events during a long-term follow-up in a contemporary European cohort.
Introduction
Statin therapy is the cornerstone of contemporary prevention of cardiovascular disease. This holds true for both primary and secondary prevention. However, a substantial number of statintreated patients who are in the recommended range of low-density lipoprotein cholesterol (LDL-C) levels still develop cardiovascular events. 1, 2 One of the markers shown to have predictive value for residual cardiovascular risk is C-reactive protein.
The Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) tested the efficacy of rosuvastatin in the primary prevention setting among individuals with low LDL-C (,3.4 mmol/L) but with slightly elevated C-reactive protein (≥2 mg/L) levels (e.g. above median in the US population). 3 In this population, rosuvastatin 20 mg resulted in a significant reduction of cardiovascular events. The results of the JUPITER trial have led to considerable debate about the value of rosuvastatin therapy in primary prevention per se. First, the percentage of individuals meeting the JUPITER criteria is unknown in a contemporary European population. Secondly, some describe the JUPITER population as an apparently healthy population with slightly elevated C-reactive protein levels only. Others have pointed to the high prevalence of metabolic syndrome, insulin resistance, and relatively high apo B levels in JUPITER. Therefore, whether this population was truly at low cardiovascular risk based on established risk factors has been a topic of debate. Thirdly, controversy exists about the absolute risk of cardiovascular events in JUPITER-eligible individuals compared with those in other C-reactive protein and LDL-C strata. 4 -7 Fourthly, it is unknown how many individuals in a European population are eligible for primary prevention according to the JUPITER criteria when compared with the European Society of Cardiology Systematic COronary Risk Evaluation (SCORE) and the Adult Treatment Panel III-Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III) guidelines. 8 The first objective of this study was to assess the proportion of individuals fulfilling the JUPITER criteria in the EPIC-Norfolk prospective population study, a contemporary European cohort based in Norfolk, UK. Additional objectives were to determine the cardiovascular risk profile and the risk of future coronary heart disease (CHD) events among JUPITER-eligible individuals in EPIC-Norfolk when compared with those in other LDL-C and C-reactive protein strata, and compared with JUPITER itself. The fourthly objective was to quantify the proportion of individuals eligible for primary prevention with statin therapy when applying the JUPITER criteria when compared with the SCORE and ATP III criteria.
Methods

Data sources
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort study is a prospective population study of 25 639 men and women aged 45 -79 years old and living in Norfolk, UK, as described previously. 9 Briefly, EPIC-Norfolk is part of the 10-country collaborative EPIC study designed to investigate determinants of cancer. From the onset, additional data were obtained in EPIC-Norfolk to enable the assessment of determinants of other diseases such as CHD. Participants were enrolled between 1993 and 1997. They completed a detailed health and lifestyle questionnaire and attended a clinic visit where additional data collection was performed by trained nurses. The study cohort was similar to UK population samples with regard to many characteristics, including anthropometry, blood pressure, and lipids, but with a lower proportion of smokers. Baseline prevalence of diabetes mellitus was ascertained by means of self-report of diabetes, diabetic diet, diabetes-specific medication, or diabetes-specific medication brought to the clinical visit. Baseline cardiovascular disease was defined by self-reported myocardial infarction or stroke. The Norwich District Health Authority Ethics Committee approved the study, and all participants gave signed informed consent.
Figure 1 EPIC-Norfolk study participants meeting the JUPITER inclusion criteria. Flow chart displaying the inclusion and exclusion criteria in sequential order of application to EPIC-Norfolk study participants. The group meeting the C-reactive protein and low-density lipoprotein cholesterol criteria of the JUPITER trial has been labeled 'JUPITER eligible.' CVD, cardiovascular disease.
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Study design
For the current analysis, we applied the JUPITER inclusion and exclusion criteria as accurately as possible with the data available in EPICNorfolk ( Figure 1 ). Men 50 years of age or older and women 60 years of age or older were eligible for the analysis if they did not have a history of cardiovascular disease and if, at the initial screening visit, triglyceride levels were ,5.6 mmol/L. Study participants for whom LDL-C or C-reactive protein levels were not available, were excluded. Additional exclusion criteria were previous or current use of lipid-lowering therapy, current use of post-menopausal hormonereplacement therapy, diabetes mellitus, uncontrolled hypertension (systolic blood pressure .190 mmHg or diastolic blood pressure .100 mmHg), uncontrolled hypothyroidism as evidenced by a thyroid-stimulating hormone (TSH) level .7.5 U/L. Because TSH levels were available in approximately half the cohort, this latter exclusion criterion was applied only in individuals for whom TSH was available. Baseline characteristics did not differ significantly between those for whom TSH was or was not available. Since sufficient baseline information was not available on all JUPITER criteria, we did not apply the following exclusion criteria: hepatic dysfunction, a creatine kinase level more than three times the upper limit of the normal range, a creatinine level that was .2.0 mg/dL (176.8 mmol/L), cancer within 5 years before enrolment, and a recent history of alcohol or drug abuse. Patients using immunosuppressant agents or long-term oral glucocorticoids were not excluded because this information was not readily available.
Biochemical analysis
Non-fasting blood samples were drawn into plain and citrate bottles. Blood samples were processed directly at the Department of Clinical Biochemistry, University of Cambridge, or stored at 2808C. Serum levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured in fresh samples with the RA 1000 (Bayer Diagnostics, Basingstoke, UK). Low-density lipoprotein cholesterol-C levels were calculated using the Friedewald formula. When additional funding became available in 2010, serum concentrations of C-reactive protein were measured in all participants with available frozen baseline serum samples using a full-range, highsensitivity assay on an Olympus AU640 clinical chemistry analyzer (Olympus UK Ltd, Watford, UK).
Outcome definitions
All individuals have been flagged for mortality at the UK Office of National Statistics, with vital status ascertained for the entire cohort. Death certificates were coded by trained nosologists according to the International Classification of Diseases 10th revision (ICD-10). In addition, hospitalized participants were identified by using their unique National Health Service number through data linkage with the East Norfolk Health Authority (ENCORE) database, which identifies all hospital contacts throughout England and Wales for residents of Norfolk. Participants were identified as having developed CHD during the follow-up if they had a hospital admission and/or died with CHD as the underlying cause during the follow-up. Coronary heart disease was defined as ICD-10 codes I20-I25 (including acute and old myocardial infarction, angina, and other ischaemic heart disease). We report results with follow-up to 31 March 2008.
Statistical analysis
The population fulfilling all inclusion criteria was classified into four groups using the LDL-C cut-off value 3.4 mmol/L and the C-reactive protein cut-off value 2 mg/L. mean + SD for continuous variables with normal distribution, median, and inter-quartile range for continuous variables with non-normal distribution, or percentage (number) for categorical variables. Baseline characteristics were compared between the groups with high vs. low C-reactive protein using a two-sided Student's t-test for continuous variables. C-reactive protein and triglycerides had a skewed distribution and were log-transformed before analysis. Differences in dichotomous variables between groups were analysed by x 2 test. The
Framingham risk score (FRS) was calculated using a previously reported algorithm, which takes into account age, sex, total cholesterol, HDL-C, systolic and diastolic blood pressure, smoking, and the presence of diabetes mellitus. 10 Cox proportional hazard models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (95% CI) for the risk of future CHD. Models were adjusted for age, sex, smoking, systolic blood pressure, HDL cholesterol, and body mass index. Categories were based on quartiles. The lowest category was used as a reference category. Kaplan-Meier curves for CHD-free survival were computed for participants classified into the four groups. Differences between curves were assessed by the log-rank test. Statistical analyses were performed using the SPSS software (version 17; SPSS, Inc., Chicago, IL, USA). A P-value of ,0.05 was considered to be statistically significant.
Results
Consistent with the JUPITER exclusion criteria, we excluded individuals with known diabetes mellitus (n ¼ 314), known prevalent cardiovascular disease (n ¼ 646), triglycerides ≥500 mg/dL (n ¼ 16), systolic blood pressure ≥190 mmHg (n ¼ 84), diastolic blood pressure ≥100 mmHg (n ¼ 655), hypothyroidism (n ¼ 125), on lipid-lowering therapy (n ¼ 137), and/or taking hormonal replacement therapy (n ¼ 417) (Figure 1) . Also, individuals without C-reactive protein measurements (n ¼ 4333) or LDL-C measurements (n ¼ 585) were excluded. The set of study participants fulfilling the inclusion criteria for whom all relevant data were available comprised 8397 individuals.
Of the total group of age-eligible study participants for whom relevant data were available, 846 individuals Table 1 . Regardless of LDL-C levels, individuals with C-reactive protein ≥2 mg/L were more likely to be older, female, smokers, and to have a higher systolic blood pressure. They also had a higher body mass index, higher waist circumference, and higher waist hip ratio. Table 2 shows that the baseline characteristics of the JUPITER-eligible subjects in EPIC-Norfolk were comparable with the JUPITER treatment arms, although the body mass index was lower in EPIC-Norfolk than in both JUPITER arms.
The distribution of the FRS across groups based on LDL-C and C-reactive protein is shown in Table 3 . In the JUPITER-eligible group, 33.8% had an intermediate FRS and 25.9% had a high FRS. The FRSs in the JUPITER-eligible individuals were higher in men than women, with 78% of women having a low FRS. The distribution across FRS categories was significantly different in Group 1 vs. 2, among men, among women, and among combined sexes. The same was true for the comparison of Group 3 vs. 4.
In the JUPITER-eligible group, the absolute rate of CHD events was 15.6% over a mean follow-up of 11.4 years (1.37%/ year). The HR for future CHD was 1.70 (95% CI: 1.31-2.21) in the JUPITEReligible group, compared with the Group 1 (LDL-C ,3.4 mmol/L and C-reactive protein ,2 mg/L) and the HR for Group 3 (LDL-C ≥3.4 mmol/L and C-reactive protein ,2 mg/L) was 1.29 (95% CI: 1.01 -1.64) ( Table 4) . Thus, individuals with high C-reactive protein and low LDL-C had higher absolute event rates than individuals with low C-reactive protein and high LDL-C. In the subanalysis 
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for the JUPITER-eligible men, the absolute event rate was 17.2% over a mean follow-up of 11.4 years (1.5% per year). The HR for future CHD was 1.97 (95% CI: 1.46 -2.66) compared with Group 1. Similarly among women, event rates were higher in Group 2 compared with Group 1 and 3. The adjusted HR was not increased in Group 2 compared with Group 1, but this is explained by the higher burden of FRS risk factors in this group ( Table 3) . Kaplan-Meier curves for survival free of CHD are shown in Figure 2 . The groups in the descending order of probability of CHD event-free survival are Groups 1, 3, 2, and 4. In the group eligible for primary prevention and with relevant data available (n ¼ 8397), 3745 (44.6%) had an indication for statin therapy according to the SCORE guidelines, whereas 4652 subjects (55.4%) did not. Among these individuals who did not have an indication for statin therapy according to the ESC guidelines, 846 subjects (18.2%) fulfilled the JUPITER criteria and would thus qualify for statin therapy independent of the SCORE guidelines. According to the US ATP III guideline, in the group eligible for primary prevention and with relevant data available (n ¼ 8397), 3931 (46.8%) had an indication for statin therapy, whereas 4466 subjects (53.5%) did not. Among these individuals who did not have an indication for statin therapy according to the ATP III guideline, 846 subjects (18.9%) fulfilled the JUPITER criteria and would thus qualify for statin therapy independent of the ATP III guideline.
Discussion
The results of the JUPITER trial have answered many questions, but several issues remain debated or unresolved. In the EPIC-Norfolk prospective population study, a contemporary cohort representative of a Western European population, 10% of study participants without prevalent cardiovascular disease met the JUPITER inclusion criteria. We observed that the cardiovascular risk profile of EPICNorfolk participants meeting the JUPITER criteria was considerable, with almost 60% having an intermediate or high FRS. We also observed that JUPITER-eligible people had a similar CHD event rate as those in the placebo arm of JUPITER (1.37 vs. 1.36%/year) and that this risk, in fact, persisted over a follow-up of 11.4 years. The proportion of individuals fulfilling the JUPITER criteria who did not qualify for statin treatment according to the SCORE and ATP III guideline was considerable (18.2, and 18.9%, respectively).
The proportion of individuals meeting the JUPITER criteria in the EPIC-Norfolk population is 10%, which is lower than the 19.8% reported in the JUPITER trial itself. It is also lower than the 18.2% reported in ARIC. 7 It is, however, comparable with data from the NHANES study which showed that 13.9% of the age-eligible population fulfilled the JUPITER criteria. the increasing burden of obesity over the years, the current burden of obesity-related risk factors in the EPIC-Norfolk population may now be more similar to those of the JUPITER population than the baseline risk factors used in our analyses. It is unclear to what extent these changes in risk factor burden over time impact on the associated risk estimates, but it is a well-known phenomenon that the predictive value of risk factors dilutes over time.
The JUPITER population has been described as an apparently healthy population with slightly elevated C-reactive protein levels alone. The distribution of the FRS is comparable with the JUPITER; 40.3% of the JUPITER-eligible subjects have a low FRS, compared with 49.9% in the JUPITER. In recent analysis of JUPITER, the relative risk reductions remained highly significant even for those very low FRS. 13 However, the cardiovascular risk profile of the JUPITER-eligible individuals in EPIC-Norfolk demonstrated that almost 60% of the individuals have an intermediate or high FRS. This percentage is higher than in NHANES, where an intermediate or high FRS was seen in .45% of the subjects.
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The risk profile also differs substantially from ARIC, which observed that only 11.7% of the JUPITER-eligible individuals had an intermediate to high FRS. Most of those subjects in ARIC, 68.7%, showed a low FRS. We assume that this result is due to differences in relevant risk factors. The JUPITER trial differs with our eligible subjects in systolic and diastolic blood pressure and total cholesterol. Nonetheless, our findings may favour the use of C-reactive protein levels to better guide cardiovascular risk prediction and reduction strategies, and points out how continued reliance on a global score like Framingham in a European setting may lead to incorrect assumptions about absolute risk as has been discussed previously in the ARIC and Women's Health Study. 6, 14 In the current study individuals that fulfilled the JUPITER criteria (C-reactive protein ≥2 mg/LDL-C ,3.4 mmol/L), and compared with those with C-reactive protein ,2 mg/LDL-C ,3.4 mmol/L, had a 10 person-year event rate of 14.6 vs. 7.0% and HR for future CHD of 1.70 (95% CI: 1.31-2.21). Furthermore the JUPITER criteria group had a higher event rate and CHD risk compared with those with higher LDL-C (≥3.4 mmol/L) and lower C-reactive protein (,2 mg/L). These data are comparable with observations from the JUPITER placebo arm, and also with findings from the ARIC study, where comparable events rates were seen over a period of 6.9 years (1.57%/year). These data contribute to evidence supporting a role for C-reactive protein in risk assessment, which was also found previously in the Women's health study and the AFCAPS/TexCAPS population in the USA. 5, 6 The increased risk in people fulfilling the JUPITER criteria persisted over a follow-up of 11.4 years in this European population, underlining that slightly increased C-reactive protein levels without normal LDL-C are associated with major vascular events over a longer period of time in Europe as well as in the USA. Application of the JUPITER criteria in addition to recommendations from the SCORE and ATP III guidelines would have resulted in an additional 18.2 and 18.9% of the age-eligible population qualifying for statin therapy for primary prevention. To ensure that those at greatest risk will be considered for prevention, alignment of guideline recommendations with incorporation of the JUPITER criteria seems desirable.
Several aspects of this study need to be considered when interpreting the results. A limitation is the fact that EPIC-Norfolk lipid levels were measured in non-fasting samples, whereas in JUPITER measurements were performed in fasting samples. This may have led to a slight inflation of the number of individuals excluded based on elevated triglyceride levels, a number which was still only modest (n ¼ 16). It may also have led to misclassification due to underestimated LDL-C levels. It is unlikely that this would have led to a bias in C-reactive protein levels. Individuals with known diabetes were excluded as was true in JUPITER, but undiagnosed diabetes was not taken into account as glycated haemoglobin levels were available in just a subset of the cohort. Another limitation was the fact that CHD events were not adjudicated. Also, it is important to note that we did not include stroke as an outcome in this analysis. In most studies C-reactive protein is a better predictor of stroke than LDL-C, 15 therefore one may suggest that overall effects are underestimated. We analysed eligibility based on single measurements of risk factors during the first visit for the EPIC-Norfolk study, whereas repeated measurements are recommended. Similarly, initiation of statin therapy is recommended after a period of lifestyle adjustment. As a consequence, our estimates of the number of individuals who were recommended treatment may be slightly overestimated. Finally, it should be noted that extrapolation of the EPIC-Norfolk results should be done with caution since they apply to the EPIC-Norfolk population with its inherent inclusion criteria, selection process, and population characteristics.
In conclusion, our data from the EPIC-Norfolk cohort reinforce the fact that JUPITER-eligible individuals are at an increased risk of CHD compared with those with low C-reactive protein in a European population and therefore the JUPITER data may be of interest for future European guidelines on cardiovascular disease prevention in clinical practice. Application of the JUPITER criteria qualified almost one-fifth of the population for statin therapy that would not have otherwise qualified based on SCORE and ATP III criteria.
